Friday 6 November 2026
Export CRL’s income statement to Excel — free account
Charles River Laboratories International, Inc.
CRL Healthcare Diagnostics & Research
Charles River Laboratories International, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, down 0.85% from fiscal 2024.
- Revenue
- −2.20%
- EPS
- +530.3%
- Free cash flow
- +16.3%
- Total debt
- +11.8%
Quarter to September 2026, against a year earlier
335.99
22.97
+7.34%
Follow CRL
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
8 | 5 | 4 | 5 |
+8 more TTM periods Free account |
| 1.21% | (7.69%) | (6.01%) | (4.35%) | ||
| 0.54% | (3.16%) | (2.41%) | (1.97%) | ||
ROIC |
1.81% | 1.07% | 0.81% | 0.31% | |
Return on Tangible Assets |
2.07% | (12.62%) | (9.69%) | (7.28%) | |
Average Days of Receivables |
67.49 | 64.96 | 63.47 | 64.44 | |
Free Cash Flow per Share |
8.36 | 7.72 | 7.99 | 10.46 | |
Free Cash Flow |
399.63 | 370.61 | 391.29 | 518.49 | |
Capital Expenditures |
(222.77) | (211.54) | (215.74) | (219.15) | |
| Other line items | |||||
Cash ROIC |
6.80% | 6.55% | 6.74% | 9.39% | |
Accounts Receivable Turnover |
5.41 | 5.41 | 5.53 | 5.62 | |
Accounts Payable Turnover |
16.88 | 18.78 | 19.25 | 18.62 | |
Inventory Turnover |
8.52 | 8.60 | 8.39 | 9.32 | |
Average Days of Payables |
19.89 | 19.11 | 17.93 | 20.17 | |
Days of Inventory on Hand |
44.00 | 46.94 | 48.15 | 40.55 | |
Tax Rate |
(1.42) | 0.29 | 0.11 | 0.43 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
18.23% | 19.06% | 18.00% | 18.51% | |
Share Based Compensation of Revenue |
2.03% | 2.08% | 1.99% | 1.77% | |
Interest Coverage |
1.45 | 0.85 | 0.66 | 0.24 | |
Operating CF/Net income |
15.49 | (2.44) | (3.29) | (5.11) | |
Depreciation/Fixed assets |
0.30 | 0.31 | 0.34 | 0.34 | |
Capex/Depreciation |
(0.50) | (0.46) | (0.42) | (0.39) | |
Revenue per Share |
83.19 | 83.28 | 82.27 | 81.01 | |
Operating CF per Share |
13.02 | 12.12 | 12.40 | 14.88 | |
Capex per Share |
(4.66) | (4.41) | (4.41) | (4.42) | |
Capex to Sales |
0.06 | 0.05 | 0.05 | 0.05 |
Columns are period end dates · fundamentals updated 5 Nov 2026